US 11,866,402 B2
Treprostinil derivatives and compositions and uses thereof
Xiaoming Zhang, Sunnyvale, CA (US); Meenakshi S. Venkatraman, Fremont, CA (US); and Cyrus K. Becker, Fremont, CA (US)
Assigned to Corsair Pharma, Inc., South San Francisco, CA (US)
Filed by CORSAIR PHARMA, INC., South San Francisco, CA (US)
Filed on Apr. 30, 2021, as Appl. No. 17/245,235.
Application 17/245,235 is a continuation of application No. 16/574,538, filed on Sep. 18, 2019, granted, now 11,034,645.
Application 16/574,538 is a continuation of application No. 15/927,636, filed on Mar. 21, 2018, granted, now 10,464,877, issued on Nov. 5, 2019.
Application 15/927,636 is a continuation of application No. 15/473,434, filed on Mar. 29, 2017, granted, now 9,957,220, issued on May 1, 2018.
Application 15/473,434 is a continuation of application No. 14/829,180, filed on Aug. 18, 2015, granted, now 9,643,911, issued on May 9, 2017.
Application 14/829,180 is a continuation in part of application No. 14/742,579, filed on Jun. 17, 2015, abandoned.
Application 14/742,579 is a continuation in part of application No. 14/742,544, filed on Jun. 17, 2015, granted, now 9,394,227, issued on Jul. 19, 2016.
Prior Publication US 2021/0355072 A1, Nov. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 69/28 (2006.01); C07C 69/734 (2006.01); C07C 69/74 (2006.01); C07C 53/136 (2006.01); C07C 59/11 (2006.01); C07C 59/13 (2006.01); A61K 9/70 (2006.01); C07D 309/08 (2006.01); C07C 69/708 (2006.01); C07C 69/712 (2006.01); C07D 305/08 (2006.01); C07C 69/675 (2006.01); C07C 69/68 (2006.01); C07C 69/75 (2006.01); C07C 69/96 (2006.01); C07D 307/24 (2006.01); C07D 307/30 (2006.01)
CPC C07C 69/734 (2013.01) [A61K 9/7023 (2013.01); C07C 53/136 (2013.01); C07C 59/11 (2013.01); C07C 59/13 (2013.01); C07C 69/28 (2013.01); C07C 69/675 (2013.01); C07C 69/68 (2013.01); C07C 69/708 (2013.01); C07C 69/712 (2013.01); C07C 69/74 (2013.01); C07C 69/75 (2013.01); C07C 69/96 (2013.01); C07D 305/08 (2013.01); C07D 307/24 (2013.01); C07D 307/30 (2013.01); C07D 309/08 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/14 (2017.05); C07C 2603/14 (2017.05)] 13 Claims
 
1. A method of promoting vasodilation, inhibiting platelet activation or aggregation, inhibiting thrombus formation, stimulating thrombolysis, inhibiting atherogenesis, inhibiting cell proliferation, promoting endothelial cell membrane remodeling, reducing inflammation, or providing cytoprotection, comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of Formula (II):

OG Complex Work Unit Chemistry
wherein:
O—Z—CO2H is

OG Complex Work Unit Chemistry
 —O-heteroalkyl-CO2H, —O-cyclyl-CO2H, —O—CH2-cyclyl-CO2H, —O-cyclyl-CH2—CO2H, or —O—CH2-cyclyl-CH2—CO2H, each of which may optionally be substituted, wherein:
cyclyl- is -cycloalkyl-, -heterocyclyl-, -aryl- or -heteroaryl-;
R7 and R8 in each occurrence independently are hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl, or R7 and R8 and the carbon atom to which they are connected form a C3-C6 cycloalkyl ring; and
n is an integer from 1 to 10;
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, polymorph or stereoisomer thereof, with the proviso that:
—O—Z—CO2H is not

OG Complex Work Unit Chemistry
 and
—O—Z—CO2H does not contain a sugar moiety.